Former Religare Enterprises chairperson Dr. Rashmi Saluja has secured an adjournment in her appeal against a SEBI insider trading penalty, pushing the hearing to October 9, 2026. The case centers on share sales made before a 2023 open offer, adding to the ongoing regulatory uncertainty surrounding the company. Investors are tracking how these legal and leadership challenges impact the stock's stability and pending business restructuring plans.
The Securities Appellate Tribunal (SAT) has adjourned the hearing regarding former Religare Enterprises executive chairperson Dr. Rashmi Saluja’s appeal against a SEBI insider trading penalty. The matter, which has drawn significant attention from shareholders and market participants, is now scheduled for further proceedings on October 9, 2026.
The Regulatory Background
This legal dispute stems from a final order issued by the Securities and Exchange Board of India (SEBI) in May 2026. The regulator investigated share transactions executed by Dr. Saluja on September 21 and 22, 2023. According to the regulator, these trades were conducted while she was in possession of non-public, price-sensitive information regarding the Burman Group’s upcoming open offer for Religare Enterprises, which was announced on September 25, 2023.
In its ruling, SEBI ordered Dr. Saluja to return the funds representing the losses she allegedly avoided, totaling approximately ₹1.99 crore. This amount is to be paid along with an interest charge of 12 percent per annum. Furthermore, the regulator imposed a separate penalty of ₹40 lakh. Dr. Saluja is currently challenging these findings at the tribunal, and the recent request for an extension has further delayed the resolution of the case.
Impact on Religare Enterprises
The ongoing legal and regulatory scrutiny comes at a critical time for Religare Enterprises. While the company’s subsidiary, Care Health Insurance, has reported robust growth in recent quarterly results as of August 2026, the parent company faces several hurdles. The stock, trading near the ₹227.50 level as of early October, has seen increased volatility as the market reacts to persistent governance questions and leadership uncertainty.
Beyond the individual legal challenges, investors are closely watching the company’s broader business strategy. Religare has been working toward a business demerger, a move aimed at unlocking value by separating its insurance and financial services businesses. However, this process has faced significant delays, largely due to regulatory hurdles and the need for various government and institutional approvals. The combination of pending restructuring plans and ongoing regulatory investigations creates a complex environment for shareholders.
Investor Monitorables
The key risk for investors remains the potential for prolonged uncertainty. When governance issues persist, they can often overshadow fundamental business performance, such as growth in insurance premiums or cost management efforts. As the October 9 hearing approaches, market participants will likely look for clarity on whether the SAT upholds the regulator’s decision or grants relief to the former chairperson. Additionally, investors may continue to track updates regarding the status of the demerger and any further regulatory actions that could impact the company’s operational stability or leadership structure.